

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Qyuns Therapeutics Co., Ltd.**  
**江蘇荃信生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2509)**

## **POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 19, 2025**

According to the notice dated December 4, 2025 (the “**Notice**”) of extraordinary general meeting (the “**EGM**”) of Qyuns Therapeutics Co., Ltd. (the “**Company**”), the EGM of the Company was held at North Conference Room, 2nd Floor, Building 1, No. 907 Yaocheng Avenue, Taizhou City, Jiangsu Province, the PRC on Friday, December 19, 2025 at 2:00 p.m. Unless otherwise defined, capitalised terms in this announcement shall have the same meaning as given to them in the Notice.

The total number of the issued Shares of the Company as at the date of the EGM was 227,071,600 H Shares, among of which, 991,800 H Shares were held by the Company as treasury shares and did not carry voting rights. For the avoidance of doubt, holder of treasury shares was not entitled to vote and had abstained from voting on the resolutions proposed at the EGM. Accordingly, the total number of H Shares entitling the holders to attend and vote for or against any of the proposed resolutions at the EGM was 226,079,800 H Shares.

As at the date of the EGM, Zhongmei Huadong, which is wholly-owned by Huadong Medicine Co., Ltd. (“**Huadong Medicine**”), held 35,900,000 H Shares of the Company, representing approximately 15.88% of the issued share capital of the Company (excluding H Shares held by the Company as treasury shares). Huadong Medicine Investment Holding (Hong Kong) Limited (“**Huadong Investment**”), which is wholly-owned by Huadong Medicine, held 1,976,800 H Shares of the Company, representing approximately 0.87% of the issued share capital of the Company (excluding H Shares held by the Company as treasury shares). Accordingly, Zhongmei Huadong and Huadong Investment are required to abstain from voting on the resolution to approve the renewal of the New Annual Caps at the EGM. As far as the Directors are aware, having made all reasonable enquiries, save for Zhongmei Huadong and Huadong Investment, no other Shareholders are required to abstain from voting on the resolutions at the EGM. There were no other H Shares entitling the shareholders to attend and abstain from voting in favour of any of the proposed resolutions at the EGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”). None of the shareholders of the Company has stated his or her intention in the Circular to vote against or abstain from voting on any resolutions at the EGM.

The number of shareholders and proxies of shareholders attending the EGM in person was 3. Shareholders and proxies of shareholders who attended the EGM in respect of resolution numbered 1 held a total of 132,578,400 H Shares with voting rights, representing approximately 70.44% of the total number of H Shares with voting rights. Shareholders and proxies of shareholders who attended the EGM in respect of resolution numbered 2 held a total of 170,455,200 H Shares with voting rights, representing approximately 75.40% of the total number of H Shares with voting rights.

The holding of the EGM was in compliance with the requirements of the Company Law of the PRC (《中華人民共和國公司法》) and the Articles of Association of the Company.

Tricor Investor Services Limited, the Company's H share registrar, acted as the scrutineer for the vote-taking at the EGM.

The following Directors of the Company attended the EGM: Mr. Qiu Jiwan, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors; Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors; and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.

## VOTING RESULTS OF THE EGM

At the EGM of the Company held on December 19, 2025, all the proposed resolutions as set out in the Notice were taken by poll. The poll results are as follows:

| Ordinary Resolution   |  | Number of Votes (%)     |              |                   |
|---|--|-------------------------|--------------|-------------------|
|   |  | For                     | Against      | Abstain           |
| 1.  | To consider and, if thought fit, approve the renewal of the New Annual Caps for the three financial years from 2026 to 2028 as set out in the Circular for the Continuing Connected Transactions under the QX001S Framework Agreement; and to authorize any Director to exercise all powers which they consider necessary and do such other acts and things and execute such other documents which in their opinion may be necessary or desirable to implement the transactions contemplated under the QX001S Framework Agreement. | 132,505,800<br>(99.95%) | 0<br>(0.00%) | 72,600<br>(0.05%) |
| As more than half of the votes were cast in favour of the resolution numbered 1, the resolution was duly passed as ordinary resolution. |  |                         |              |                   |

| Special Resolution   |  | Number of Votes (%)     |              |                   |
|--|--|-------------------------|--------------|-------------------|
|  |  | For                     | Against      | Abstain           |
| 2.   | To consider and, if thought fit, approve the proposed amendments of the articles of association. | 170,382,600<br>(99.96%) | 0<br>(0.00%) | 72,600<br>(0.04%) |
| As more than two-thirds of the votes were cast in favour of the resolution numbered 2, the resolution was duly passed as special resolution. |  |                         |              |                   |

By Order of the Board  
**Qyuns Therapeutics Co., Ltd.**  
**Mr. Qiu Jiwan**  
*Chairman of the Board and Executive Director*

Hong Kong, December 19, 2025

*As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.*